Vaccine market boosters

  title={Vaccine market boosters},
  author={Cormac Sheridan},
  journal={Nature Biotechnology},
  • C. Sheridan
  • Published 1 June 2009
  • Business
  • Nature Biotechnology
Recent commercial success belies conventional wisdom that vaccines are a low-margin, moribund sector. But will the trend continue? Cormac Sheridan investigates. 
Giving developing countries the best shot : An overview of vaccine access and R & D
An overview of vaccine access and R&D • 1 Executive summary 2 Background 5 Overview of vaccines and immunisation Vaccine markets Vaccine suppliers and business models Access to vaccines 7 The current
Are economic evaluations an important tool in vaccine policy decisions?
  • P. Jacobs
  • Political Science, Medicine
    Expert review of pharmacoeconomics & outcomes research
  • 2011
It is concluded that health economics can move some of the considerations in vaccine policy decision-making from the political to the scientific arena, but there are still many unresolved issues.
Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.
Implementing the PCV13 vaccine is projected to cost public and private payers $3.5 billion and $2.6 billion, respectively, more than PCV7, but this new vaccine is expected to provide net cost savings of $6.2 billion to payers during the ten-year period by preventing pneumococcal disease and its associated costs.
Haemophilus influenzae type b vaccine in low- and middle-income countries : impact, costs and incremental cost-utility
This PhD thesis is the first attempt to combine evidence on disease burden, costs and impact of Hib vaccine across multiple countries using a consistent framework and comparable input parameters and new insights into the relative cost-utility in countries with different economic and epidemiological circumstances are obtained.
Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market
Limits are found in existing immunotherapeutics for cancer treatment, and recent development of therapeutic cancer vaccines such as MAGE-A3 and NY-ESO-1 may provide alternative therapeutic strategy.
The evolving threat of antimicrobial resistance: Options for action
One in three adults aged over 65 in England have difficulty understanding basic health‐related information, suggests a study in the BMJ, and the Patients Association said patients should help draft information leaflets so they are "relevant and clear".
To get the shot or not? Narratives, rhetoric, and the childhood vaccination crisis
Parents in developed countries like the United States are questioning the need for and safety of childhood vaccinations. Incidences of disease have risen as fewer parents have vaccinated their
Process improvement and inventory management using value stream mapping in a biopharmaceutical environment
........................................................................................................................................................ 3 A cknow ledgm


A universal vaccine for serogroup B meningococcus.
The vaccine adjuvanted by aluminum hydroxide induced bactericidal antibodies in mice against 78% of a panel of 85 meningococcal strains representative of the global population diversity and has the potential to conquer one of the most devastating diseases of childhood.
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
The safety and immunogenicity data from this trial support further evaluation of VCL-CB01, a candidate cytomegalovirus DNA vaccine that contains plasmids encoding CMV phosphoprotein 65 and glycoprotein B to induce cellular and humoral immune responses.
A Novel Staphylococcus aureus Vaccine: Iron Surface Determinant B Induces Rapid Antibody Responses in Rhesus Macaques and Specific Increased Survival in a Murine S. aureus Sepsis Model
IsdB has excellent prospects for use as a vaccine against S. aureus disease in humans and was highly immunogenic in mice when it was formulated with amorphous aluminum hydroxyphosphate sulfate adjuvant, and the resulting antibody responses were associated with reproducible and significant protection in animal models of infection.
Vaccine prevention of maternal cytomegalovirus infection.
CMV glycoprotein B vaccine has the potential to decrease incident cases of maternal and congenital CMV infection and was more likely to remain uninfected during a 42-month period than the placebo group.